Home Cart Sign in  
Chemical Structure| 1351636-18-4 Chemical Structure| 1351636-18-4

Structure of Tirabrutinib
CAS No.: 1351636-18-4

Chemical Structure| 1351636-18-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ONO-4059 is a highly selective BTK inhibitor with IC50 of 2.2 nM.

Synonyms: ONO-4059; GS-4059; ONO-WG-307

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tirabrutinib

CAS No. :1351636-18-4
Formula : C25H22N6O3
M.W : 454.48
SMILES Code : O=C1N(C2=CC=C(OC3=CC=CC=C3)C=C2)C4=C(N)N=CN=C4N1[C@H]5CN(C(C#CC)=O)CC5
Synonyms :
ONO-4059; GS-4059; ONO-WG-307
MDL No. :MFCD28386296
InChI Key :SEJLPXCPMNSRAM-GOSISDBHSA-N
Pubchem ID :54755438

Safety of Tirabrutinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Tirabrutinib

RTK

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02457559 Relapsed/Refractory B-cell Mal... More >>ignancies Less << PHASE1 COMPLETED 2020-12-30 CHRU de Lille, Lille, Nord, 59... More >>037, France|Hopital Saint Eloi, Montpellier, 34295, France|Centre Hospitalier Lyon Sud, Pierre Benite, 69310, France|University Hospital of Wales, Cardiff, CF14 4XW, United Kingdom|Leicester Royal Infirmary, Leicester, LE1 5WW, United Kingdom|Derriford Hospital, Plymouth, PL68DH, United Kingdom Less <<
NCT01659255 Non Hodgkins Lymphoma|Chronic ... More >>Lymphocytic Leukaemia Less << PHASE1 COMPLETED 2016-01-11 CHRU - Hopital Claude HURIEZ, ... More >>Lille, 59037, France|Centre hospitalier Lyon Sud, Lyon, 69495, France|CHU St Eloi, Montpellier, 34295, France|University Hospital of Wales, Cardiff, CF14 4XW, United Kingdom|Leicester Royal Infirmary, Leicester, LE1 5WW, United Kingdom|Derriford Hospital, Plymouth, PL6 8DH, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.20mL

0.44mL

0.22mL

11.00mL

2.20mL

1.10mL

22.00mL

4.40mL

2.20mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories